Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Wellington F Silva, MD, Lidiane Inês Da Rosa, MD, Fernanda S Seguro, MD, Douglas R. A. Silveira, Luciana Nardinelli, M.Sc, Valeria Buccheri, MD PhD, Elvira DRP Velloso, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1354.

https://doi.org/10.1182/blood-2019-127202

Published: 2019

Journal Articles

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Nayara Ribeiro Guedes, MD, Ana Rita Da Fonseca, MD, Thiago Xavier Carneiro, MD PhD, Vinicius Campos de Molla, MD, Rodrigo Santucci Silva, MD, Sérgio Costa Fortier, MD, Vera Lucia de Piratininga Figueiredo, MD, Larissa Ommati, MD, Valeria Buccheri, MD PhD, Gislaine Borba Oliveira, MD, Leila Martins Perobelli, MD, Fernando Sergio Blumm Ferreira, MD, Matheus Vescovi, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 1764.

https://doi.org/10.1182/blood-2019-125626

Published: 2019

Journal Articles

WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil

Elvira DRP Velloso, MD PhD, Maria Gabriella Cordeiro, Danielle Lucon, PhD, Renata Kishimoto, Aline Medeiros Leal, PhD, Ana Carolina Arrais Maia, MD, Valeria Buccheri, MD PhD, Israel Bendit, MD PhD, Wellington Fernandes Silva, Jr., MD, Cristovao Mangueira, MD PhD, Eduardo Magalhães Rego, MD PhD, Vanderson Rocha, MD PhD

Blood (2018) 132 (Supplement 1): 5288.

https://doi.org/10.1182/blood-2018-99-115426

Published: 2018

Journal Articles

Open-Label Early-Access Programs (EAPs) for Ibrutinib in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) or Mantle-Cell Lymphoma (MCL)

Carlos Sérgio Chiattone, MD, Nelson Hamerschlak, MD PhD, Laura Fogliatto, Phillip Scheinberg, MD, Ricardo Bigni, MD MPH, Celso Rodrigues, MD PhD, Bernardo Garicochea, Alex Pimenta, Tiago Oliveira Boechat, MD, Juliane Musacchio, MD PhD, Jaisson Bortolini, MD, Iara Zapparoli Goncalves, MD, Garles Miller Matias Vieira, Valeria Buccheri, MD PhD, Telma Santos, Mariana Grings, Lori Parisi, Paula Barreyro, MD

Blood (2018) 132 (Supplement 1): 5554.

https://doi.org/10.1182/blood-2018-99-116720

Published: 2018

Journal Articles

Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341)

Sarit Assouline, MD MSc, Valeria Buccheri, MD PhD, Alain Delmer, MD, Gianluca Gaidano, MD PhD, Michael Brewster, BSc, Olivier Catalani, Sai Li, MD PhD, Christine McIntyre, PhD, Pakeeza Sayyed, PhD, Xavier C Badoux, MBBS

Blood (2014) 124 (21): 1995.

https://doi.org/10.1182/blood.V124.21.1995.1995

Published: 2014

Journal Articles

Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

Sarit Assouline, Valeria Buccheri, MD; PhD., Alain Delmer, MD, Gottfried Doelken, MD, Gianluca Gaidano, MD, PhD, Christine McIntyre, Mike Brewster, Florence Hourcade-Potelleret, PhD, Pakeeza Sayyed, Xavier Badoux, MB BS FRACP FRCPA

Blood (2012) 120 (21): 1637.

https://doi.org/10.1182/blood.V120.21.1637.1637

Published: 2012

Journal Articles

Hodgkin Lymphoma: 20 Years Experience From a Single Brazilian Institution

Camila C.G. Linardi, MD; PhD., Luis Fernando Pracchia, MD., Rodrigo Dolphini Velasques, MD., Claudia Bitti Barroso, MD, Valeria Buccheri, MD; PhD.

Blood (2011) 118 (21): 3153.

https://doi.org/10.1182/blood.V118.21.3153.3153

Published: 2011

NARROW

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil

Open-Label Early-Access Programs (EAPs) for Ibrutinib in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) or Mantle-Cell Lymphoma (MCL)

Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

Hodgkin Lymphoma: 20 Years Experience From a Single Brazilian Institution

Email alerts

ASH Publications

American Society of Hematology

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil

Open-Label Early-Access Programs (EAPs) for Ibrutinib in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) or Mantle-Cell Lymphoma (MCL)

Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

Hodgkin Lymphoma: 20 Years Experience From a Single Brazilian Institution

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only